News | February 07, 2022
India grants Emergency Use Authorisation to Sputnik Light
This is the ninth Covid-19 vaccine approved in India
This is the ninth Covid-19 vaccine approved in India
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
It has also been granted permission to conduct trials for booster dose
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
Subscribe To Our Newsletter & Stay Updated
